Lilly’s Eczema Contender Promising, But Needs Head-To-Head Data To Dent Dupixent Dominance
Also Vital For Partners Almirall
Lilly is also awaiting FDA judgement on its JAK inhibitor Olumiant in atopic dermatitis, a fast expanding market for biologics. 
